Predicted outcome (8-week mortality) from multivariate analysis by number of adverse prognostic factors
| No. of adverse factors . | No. of patients (%) . | 8-wk mortality, % . | CR, % . | Survival . | ||
|---|---|---|---|---|---|---|
| Median, mo . | 2-y, % . | 3-y, % . | ||||
| 0 | 122 (28) | 16 | 57 | 11.3 | 30 | 22 |
| 1 | 170 (40) | 31 | 52 | 5.3 | 15 | 7 |
| 2 | 100 (23) | 55 | 29 | 1.5 | 7 | 6 |
| ≥ 3 | 38 (9) | 71 | 16 | 0.5 | 0 | 0 |
| No. of adverse factors . | No. of patients (%) . | 8-wk mortality, % . | CR, % . | Survival . | ||
|---|---|---|---|---|---|---|
| Median, mo . | 2-y, % . | 3-y, % . | ||||
| 0 | 122 (28) | 16 | 57 | 11.3 | 30 | 22 |
| 1 | 170 (40) | 31 | 52 | 5.3 | 15 | 7 |
| 2 | 100 (23) | 55 | 29 | 1.5 | 7 | 6 |
| ≥ 3 | 38 (9) | 71 | 16 | 0.5 | 0 | 0 |
Adverse factors for 8-week mortality were age ≥ 80 years (OR, 2.13; P = .016), performance status ≥ 2 ECOG score (OR, 3.25; P < .001), complex karyotype (≥ 3 abnormalities; OR, 2.07; P = .001), and creatinine level > 1.3 mg/dL (OR, 1.96; P = .005)
CR indicates complete response; ECOG, Eastern Cooperative Oncology Group; abn, abnormality; and OR, odds ratio.